Moderna, Inc. (ETR:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
34.19
-2.10 (-5.80%)
At close: Feb 6, 2026
1.32%
Market Cap13.56B -13.4%
Revenue (ttm)1.90B -56.1%
Net Income-2.66B
EPS-6.86
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,785
Average Volume30,307
Open34.41
Previous Close36.29
Day's Range33.45 - 35.18
52-Week Range19.37 - 46.96
Beta1.34
RSI48.48
Earnings DateFeb 13, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline

Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline

2 days ago - GuruFocus

Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling

What's next for the vaccine giant?

2 days ago - The Street

RSP, SNDK, WDC, MRNA: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Equal Weight ETF (Symbol: RSP) where we have detected ...

3 days ago - Nasdaq

Interesting MRNA Put And Call Options For March 27th

Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the March 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options ...

3 days ago - Nasdaq

Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the  Defiance Daily Target 2X Long MRNA ETF (MRNX) , expanding its lineup of single-stock leveraged ETFs designed f...

4 days ago - GlobeNewsWire

TD Waterhouse Canada Inc. Sells 534 Shares of Moderna Inc (MRNA)

TD Waterhouse Canada Inc. Sells 534 Shares of Moderna Inc (MRNA)

4 days ago - GuruFocus

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

Moderna CEO Stéphane Bancel discusses positive cancer vaccine trial results and the impact GLP-1 drugs on 'Mornings with Maria.' #foxbiusiness #morningswithmaria

4 days ago - Fox Business

Moderna said revenue would grow in 2026 for the first time since 2021, says Jim Cramer

'Mad Money' host Jim Cramer looks back at the S&P 500 winner in January.

5 days ago - CNBC

Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings

Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings

5 days ago - GuruFocus

Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal Battle with Moderna

Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal Battle with Moderna

5 days ago - GuruFocus

Goldman Sachs Innovate Equity ETF Buys 2,395 Shares of Moderna Inc (MRNA)

Goldman Sachs Innovate Equity ETF Buys 2,395 Shares of Moderna Inc (MRNA)

6 days ago - GuruFocus

PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)

PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)

8 days ago - GuruFocus

Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)

Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)

8 days ago - GuruFocus

Noteworthy Friday Option Activity: V, MRNA, WDC

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Visa Inc (Symbol: V), where a total of 45,386 contracts have traded so far, representing approxi...

9 days ago - Nasdaq

Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift

Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift

9 days ago - GuruFocus

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi ...

9 days ago - Seeking Alpha

Moderna CMO Jacqueline Miller to step down

Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.

9 days ago - Reuters

Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Offi...

9 days ago - Finanz Nachrichten

Dr. David Berman to Join Moderna as Chief Development Officer

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...

9 days ago - Accesswire

Dr. David Berman to Join Moderna as Chief Development Officer

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...

9 days ago - Wallstreet:Online

Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing

Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing

9 days ago - GuruFocus

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

mRNA-3927 is a strong strategic fit with Recordati's rare Metabolic portfolio Collaboration combines Moderna's expertise in mRNA technology for rare metabolic disorders with Recordati's established gl...

9 days ago - GlobeNewsWire